A cathepsin-like cysteine proteinase proaggregating activity in thrombotic thrombocytopenic purpura
- 1 November 1991
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 79 (3) , 474-480
- https://doi.org/10.1111/j.1365-2141.1991.tb08058.x
Abstract
The platelet aggregating activity (PAA) of serum and plasma from thrombotic thrombocytopenic purpura (TTP, eight patients) and haemolytic uraemic syndrome (HUS, three patients) was investigated. Sample-induced aggregation of washed platelets and the parallel 3H-serotonin release were studied both in the presence and the absence of purified von Willebrand factor (vWF) or defibrinated cryoprecipitate, according to Kelton et al (1987). All the samples but two were positive in the test, vWF being indispensable for aggregation in all but two of the active cases. Samples from five patients during remission were ineffective under the same conditions, as were 14 controls from healthy donors. An inhibition study using four cysteine proteinase inhibitors (1 mM iodoacetamide, 0.5 mM E-64, 0.1 mM antipain and 0.1 mM leupeptin) and two serine proteinase inhibitors (200 U/ml aprotinin and 0.2 U/ml hirudin) confirmed that TTP/HUS's PAA behaved enzymatically as a cysteine proteinase, as described (Murphy et al, 1987a). These results were confirmed on a protein preparation obtained from pooled plasmas after Al(OH)3 adsorption, ammonium sulphate precipitation, binding to and elution from a p-(chloromercuri)benzoate (PCMB) affinity resin. To further characterize this activity we investigated whether it was a calcium-dependent neutral protease or a lysosomal cathepsin by testing the sensitivity to a series of peptidyl diazomethyl ketones, synthetic inhibitors specifically designed for cysteine proteinases. We confirm here the presence of a circulating platelet aggregating cysteine proteinase in TTP/HUS and provide evidence for the first time that this activity behaves like a lysosomal cathepsin.Keywords
This publication has 17 references indexed in Scilit:
- Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndromeBlood, 1989
- Inhibition of cancer procoagulant by peptidyl diazomethyl ketones and peptidyl sulfonium saltsThrombosis Research, 1989
- The design of peptidyldiazomethane inhibitors to distinguish between the cysteine proteinases calpain II, cathepsin L and cathepsin BBiochemical Journal, 1988
- Relationship between platelet aggregating factor and von Willebrand factor in thrombotic thrombocytopenic purpuraBritish Journal of Haematology, 1987
- Decreased level of calpain inhibitor activity in red blood cells from Milan hypertensive ratsBiochemical and Biophysical Research Communications, 1986
- Novel platelet-agglutinating protein from a thrombotic thrombocytopenic purpura plasma.Journal of Clinical Investigation, 1985
- Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissueBiochemistry, 1985
- Detection of a Platelet-Agglutinating Factor in Thrombotic Thrombocytopenic PurpuraAnnals of Internal Medicine, 1984
- Tumor Cell-Platelet Aggregation: Induced by Cathepsin B-Like Proteinase and Inhibited by ProstacyclinScience, 1982
- [41] Cathepsin B, cathepsin H, and cathepsin LPublished by Elsevier ,1981